John P. Jakupciak

John P. Jakupciak

Auto-generated profile, based on publicly available information

John P. Jakupciak

National Institute of Standards and Technology, Biochemical Science Division, Gaithersburg, MD 20899, USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2005 in The Journal of Molecular Diagnostics
Verified
Journal Article
Closed access
JJJohn P. Jakupciak
John P. Jakupciak
WWWendy Wang
Wendy Wang
MMMaura E. Markowitz
Maura E. Markowitz
DADelphine Ally
Delphine Ally
MCMichael Coble
Michael Coble
COCatherine D. O'COnnell
Catherine D. O'COnnell

1 December 2006
Verified
Journal Article
Closed access
JJJohn P Jakupciak
John P Jakupciak
GDGabriel D Dakubo
Gabriel D Dakubo
SMSamantha Maragh
Samantha Maragh
RPRyan L Parr
Ryan L Parr

28 November 2006 in Cancer Letters
Verified
Journal Article
Closed access
PDF file
BMBrenna M. McGruder
Brenna M. McGruder
DADonald H. Atha
Donald H. Atha
WWWendy Wang
Wendy Wang
KHKonrad Huppi
Konrad Huppi
WWWen-Qiang Wei
Wen-Qiang Wei
JJJohn P. Jakupciak
John P. Jakupciak

1 November 2005 in Cancer Biomarkers
Verified
Journal Article
Closed access
PDF file
COCatherine D. O'COnnell
Catherine D. O'COnnell
DADonald H. Atha
Donald H. Atha
JJJohn P. Jakupciak
John P. Jakupciak
As large scale genomics and proteomics efforts identify an increasingly complex list of biomarkers to identify human disease, populations predictive for that disease, and drug or other therapy responses for treatment, attention is needed in the resea

1 September 2005 in Expert Review of Molecular Diagnostics
Verified
Journal Article
Closed access
JJJohn P Jakupciak
John P Jakupciak
Since the hallmark report of the PCR-based telomeric repeat amplification protocol (TRAP) in 1994, there has been a flurry of investigations of telomerase activity on normal, benign, premalignant and cancerous samples representative of the various stages of tumorigenesis. Basic research and technological advances in human genetics, biochemistry and model systems have brought much progress towards the understanding of human infectious, hereditary and somatically acquired diseases. The knowledge of carcinogenesis has increased very rapidly in the past few years, particularly with the development of automated molecular biologic analysis of tumors and preneoplastic lesions. Despite the wide variety of studies on the potential use of telomerase as a cancer biomarker, the variability of reported telomerase activity and the lack of a transferable detection method have prevented it from becoming a routine clinical application. Real-time PCR is a clinically transferable method and the advancement of real-time measurements of telomerase will facilitate moving telomerase activity and technologies towards clinical validation. It is expected that the next 5 years will see telomerase integrated into the initial detection and follow-up monitoring of cancer patients. The hope is that the use of telomerase will finally translate into a diagnostic to help realize longer survival and a better quality of life.